Oragenics, Inc. (OGEN)
-0.007 (-0.66%)
Apr 23, 2024, 12:45 PM EDT - Market open

Company Description

Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States.

The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.

The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries.

It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs.

The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

Oragenics, Inc.
Oragenics logo
Country United States
Founded 1996
Industry Biotechnology
Sector Healthcare
Employees 5
CEO Charles L. Pope CPA

Contact Details

1990 Main Street, Suite 750
Sarasota, Florida 34236
United States
Phone (813) 286-7900
Website oragenics.com

Stock Details

Ticker Symbol OGEN
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001174940
CUSIP Number 684023500
ISIN Number US6840235005
Employer ID 59-3410522
SIC Code 2834

Key Executives

Name Position
Charles L. Pope CPA Executive Chairman
Joseph Michael Redmond President and Interim Principal Executive Officer
Janet Huffman Chief Financial Officer, Secretary and Treasurer
Dr. James P. Kelly M.A., M.D. Chief Medical Officer and Member of Scientific Advisor

Latest SEC Filings

Date Type Title
Apr 22, 2024 8-K Current Report
Apr 16, 2024 8-K Current Report
Mar 29, 2024 10-K Annual Report
Mar 18, 2024 8-K Current Report
Mar 6, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Mar 1, 2024 8-K Current Report
Feb 29, 2024 424B5 Filing
Feb 28, 2024 8-K Current Report
Feb 28, 2024 8-K Current Report
Feb 27, 2024 FWP Free Writing Prospectus